{"gene":"PLCG2","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2012,"finding":"In-frame genomic deletions within the autoinhibitory domain of PLCG2 result in protein products with constitutive phospholipase activity. Cells expressing these deletion proteins show diminished cellular signaling at 37°C but enhanced signaling at subphysiologic temperatures, establishing that the deleted region encodes an autoinhibitory domain critical for temperature-dependent regulation.","method":"Sequencing of cDNA and genomic DNA from patients; enzymatic assays measuring phospholipase activity; flow cytometry-based signaling assays in patient leukocytes at different temperatures","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — enzymatic activity directly measured, multiple orthogonal methods (genetic, biochemical, functional cell assays), replicated across three families with distinct deletions","pmids":["22236196"],"is_preprint":false},{"year":2012,"finding":"The p.Ser707Tyr missense substitution in the autoinhibitory cSH2 domain of PLCγ2 causes enhanced PLCγ2 activity (hypermorphic effect) with increased intracellular signaling at physiological temperatures, establishing that the cSH2 domain normally restrains enzyme activity.","method":"Overexpression of altered protein in heterologous cells; ex vivo leukocyte signaling assays from affected patients; whole-exome sequencing to identify the de novo variant","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal confirmation by overexpression and ex vivo patient cell assays, independent replication in subsequent studies","pmids":["23000145"],"is_preprint":false},{"year":2015,"finding":"The hypermorphic p.Ser707Tyr PLCγ2 mutation causes elevated basal intracellular Ca2+ and enhanced Ca2+ flux, which drives NLRP3 inflammasome activation and IL-1β secretion in response to LPS alone; this effect is blocked by PLC inhibitors, intracellular Ca2+ blockers, or adenylate cyclase activators, placing PLCG2 upstream of the NLRP3 inflammasome via Ca2+ signaling.","method":"Western blotting for caspase-1 cleavage and IL-1β; FLIPR calcium flux assay in patient PBMCs; pharmacological inhibition with U73122 (PLC inhibitor), Ca2+ blockers, and forskolin","journal":"Arthritis & rheumatology (Hoboken, N.J.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal pharmacological interventions and biochemical readouts in primary patient cells, consistent with overexpression studies in the original report","pmids":["25418813"],"is_preprint":false},{"year":2019,"finding":"The Alzheimer's disease-protective p.P522R variant of PLCG2 produces a small hypermorphic (gain-of-function) effect on enzyme activity, as measured by multiple orthogonal assays in transfected heterologous cells.","method":"Radioactive phospholipase assay; IP-One ELISA; calcium assay in transfected COS7 and HEK293T cells","journal":"Alzheimer's research & therapy","confidence":"High","confidence_rationale":"Tier 1 / Strong — three independent orthogonal enzymatic assays in heterologous expression system confirming the same hypermorphic conclusion","pmids":["30711010"],"is_preprint":false},{"year":2019,"finding":"The p.Met1141Lys gain-of-function mutation in the C2 domain of PLCγ2 causes increased B cell receptor-triggered calcium influx and ERK phosphorylation, as demonstrated in primary patient cells and by overexpression in a PLCγ2-knockout DT40 cell line, expanding the functional domains required for autoinhibition beyond the SH2 domains.","method":"BCR-triggered calcium flux and ERK phosphorylation assays by flow cytometry in primary cells; overexpression of mutant in Plcg2-deficient DT40 B cells","journal":"Journal of clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal validation in knockout cell line plus primary patient cells, single lab","pmids":["31853824"],"is_preprint":false},{"year":2018,"finding":"A novel p.L848P missense mutation in PLCG2 causes increased basal and EGF-stimulated PLCγ2 activity in vitro, establishing this as a gain-of-function variant; unlike S707Y, it does not appear to activate the NLRP3 inflammasome as the primary inflammatory mechanism.","method":"In vitro PLC activity assay; whole blood cytokine assays; negative result for IL-1β response to IL-1 blockade","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzymatic assay plus ex vivo functional cytokine assay, single lab","pmids":["30619256"],"is_preprint":false},{"year":2020,"finding":"Two novel PLCG2 variants (p.Ala708Pro and p.Leu845_Leu848del) cause enhanced PLCγ2 enzymatic activity as measured by ex vivo calcium responses in patient B cells stimulated via IgM and by in vitro PLC activity assays; additionally, both variants activate the NLRP3 inflammasome through the alternative rather than the canonical pathway.","method":"Ex vivo calcium flux assay in patient B cells; in vitro PLC activity assay; Western blotting for inflammasome components","journal":"Journal of clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal assays (calcium flux and enzymatic assay), single lab","pmids":["32671674"],"is_preprint":false},{"year":2020,"finding":"CSF1R activation by rh-CSF1 increases phosphorylation of PLCG2, and pharmacological inhibition of PLCG2 (U73122) abolishes neuroprotective effects of rh-CSF1 in a rat hypoxic-ischemic model, placing PLCG2 downstream of CSF1R in a CSF1R/PLCG2/PKA/UCP2 signaling pathway that reduces oxidative stress and neuronal apoptosis.","method":"Western blot for p-PLCG2, p-PKA, UCP2; pharmacological inhibition with CSF1R inhibitor BLZ945 and PLCG2 inhibitor U73122; brain infarct volume, TUNEL staining, immunofluorescence in rat pups","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement by pharmacological epistasis with two inhibitors, multiple functional readouts, single lab, animal model","pmids":["33101590"],"is_preprint":false},{"year":2020,"finding":"CSF1R activation by rh-CSF1 increases p-PLCG2, p-PKCε, and p-CREB; inhibition of PLCG2 by U73122 abolishes anti-inflammatory effects, establishing a CSF1R/PLCG2/PKCε/CREB signaling pathway downstream of CSF1R in microglial neuroinflammation regulation.","method":"Western blot for pathway components; pharmacological inhibition with BLZ945 and U73122; brain edema, infarct area, and cytokine measurements in rat HIE model","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological epistasis with two inhibitors, multiple biochemical readouts, single lab, animal model","pmids":["32522286"],"is_preprint":false},{"year":2022,"finding":"PLCG2 deficiency in 5xFAD mice abolishes the increase in Plcg2 expression driven by amyloid pathology, reduces microglial association with amyloid plaques, and perturbs immune-related transcriptional pathways; PLCG2 deficiency also reduces TREM2 expression, while TREM2 deficiency increases PLCG2 expression, placing PLCG2 as a component of TREM2 signal transduction that may play an upstream regulatory role.","method":"PLCG2-deficient × 5xFAD mouse crosses; TREM2-deficient × 5xFAD crosses; bulk RNA-sequencing transcriptomics; immunostaining; correlation with human bulk RNA-seq data","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout mouse model with transcriptomic and histological readouts, single lab, corroborated by human transcriptomics","pmids":["40346446"],"is_preprint":false},{"year":2022,"finding":"PLCG2 P522R variant in human iPSC-derived microglia transplanted into chimeric AD mice induces increased HLA/antigen presentation gene expression, chemokine signaling, and T cell proliferation pathways, and promotes CD8+ T cell recruitment to the brain, demonstrating a functional role for PLCG2 in microglial antigen presentation and T cell engagement.","method":"iPSC-derived microglia (P522R vs. wild-type) transplanted into chimeric AD mice; single-cell and bulk RNA-sequencing; histological analysis of CD8+ T cell infiltration","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — iPSC microglia chimeric mouse model with single-cell transcriptomics and histology, single lab","pmids":["35142046"],"is_preprint":false},{"year":2023,"finding":"Functional classification of numerous PLCG2 variants in Plcg2-deficient DT40 B cells revealed that most functional variants define a class of monoallelic loss-of-function (LOF) mutations, while 13 variants are gain-of-function (GOF); LOF and GOF variants cause overlapping but distinct immune phenotypes, including NK cell dysfunction that can exceed B cell effects.","method":"Mutagenesis of EGFP-PLCG2 plasmid; overexpression in Plcg2-deficient DT40 cells; BCR-induced calcium flux and ERK phosphorylation by flow cytometry; primary patient cell calcium flux assays","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — systematic mutagenesis plus two orthogonal functional readouts across large variant set in defined knockout cell line, corroborated by primary patient cells","pmids":["37769878"],"is_preprint":false},{"year":2023,"finding":"PLCG2 haploinsufficiency (heterozygous loss-of-function) causes impaired NK cell calcium flux and cytotoxicity with preserved B cell function; Plcg2+/- mice phenocopy this human NK cell immunodeficiency, establishing that full PLCG2 dosage is required for normal NK cell—but not B cell—function.","method":"Whole-exome sequencing; mass cytometry; functional NK cell cytotoxicity assays; calcium flux assays; Plcg2+/- mouse model","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetic variants validated functionally in primary cells and phenocopied in a mouse model, multiple orthogonal methods","pmids":["37714437"],"is_preprint":false},{"year":2024,"finding":"The PLCG2 p.D993Y variant disrupts the interaction between catalytic and autoinhibitory domains of PLCγ2, causing autoactivation with heightened PLCγ2 phosphorylation, elevated IP3 production, intracellular Ca2+ release, and activation of MAPK, NF-κB, and NFAT signaling pathways.","method":"IP3 (inositol monophosphate) ELISA; calcium flux assay; immunoblotting for pPLCγ2; luciferase reporter assays for NF-κB/NFAT; immunoprecipitation for domain interaction; expression in HEK293T, COS-7, and PLCG2-KO THP-1 cells","journal":"Arthritis & rheumatology (Hoboken, N.J.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal biochemical assays including immunoprecipitation for domain interaction plus functional signaling readouts in multiple cell lines","pmids":["38965708"],"is_preprint":false},{"year":2024,"finding":"In-frame deletions of exons 18-19 or 19-22 in PLCG2 (caused by splice site or de novo mutations) produce proteins that fail to phosphorylate ERK in response to B cell receptor crosslinking at physiological conditions, consistent with dominant-negative function.","method":"cDNA sequencing of full-length PLCG2; whole genome sequencing; overexpression of deletion transcripts in Plcg2-deficient DT40 cells; ERK phosphorylation by flow cytometry with/without BCR crosslinking","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional validation in Plcg2-KO cell line with BCR stimulation, single lab, multiple variant confirmations","pmids":["39667583"],"is_preprint":false},{"year":2025,"finding":"PLCG2 downregulation in neurons (non-microglial) disrupts dendritic morphology, impairs synaptic function, and increases Aβ levels and tau phosphorylation in rat primary neuronal cultures and human neuronal cultures; a loss-of-function PLCG2 variant (R953*) recapitulates these synaptic and AD-related phenotypes, suggesting a neuronal role for PLCG2 in synaptic maintenance.","method":"High-content screening in rat primary neuronal cultures; PLCG2 knockdown; human neuronal culture experiments; Aβ measurement; tau phosphorylation assay; single-nuclei RNA-seq","journal":"bioRxiv : the preprint server for biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — novel mechanistic findings in neuronal cells with multiple readouts, but preprint, single lab, no replication","pmids":["41928929"],"is_preprint":true},{"year":2025,"finding":"PLCγ2 mediates spontaneous calcium oscillation in neutrophils and contributes to chemoattractant-triggered calcium response; PLCγ2-deficient (plcg2 kd) neutrophils show impaired Ca2+ oscillation, decreased membrane targeting of the RasGAP CAPRI, and increased Ras/PI3Kγ activation and actin polymerization, demonstrating that PLCγ2 gates chemoattractant concentration range for chemotaxis by controlling CAPRI membrane recruitment.","method":"Ca2+ imaging; membrane localization assays for CAPRI; Ras activation assay; PI3Kγ activity; actin polymerization assay; chemotaxis assay in plcg2 knockdown neutrophils","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays in KD neutrophils establishing pathway placement, but preprint, single lab","pmids":["bio_10.1101_2025.04.07.647573"],"is_preprint":true},{"year":2025,"finding":"A PLCG2 splice isoform lacking 65 bp from exon 28 (D65-PLCG2), generated by the rs1071644-T allele, lacks the Ca2+-binding domain and does not respond to cytosolic Ca2+ increase in the same manner as canonical PLCG2; D65-PLCG2 is susceptible to nonsense-mediated RNA decay, representing a loss-of-function mechanism.","method":"Minigene splicing assay in BV-2 microglial cells; cycloheximide treatment for NMD assessment; Ca2+ response assay comparing D65-PLCG2-GFP vs. PLCG2-GFP in transfected HEK293 cells; qRT-PCR","journal":"Molecular neurodegeneration advances","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — functional assay in transfected cells with minigene validation and NMD assessment, single lab, multiple orthogonal approaches","pmids":["41459197"],"is_preprint":false},{"year":1995,"finding":"PLCG2 maps to the long arm of human chromosome 16 (region q22-qter) and to the central region of mouse chromosome 8, distinct from the chromosomal location of the paralog PLCG1, establishing that the mammalian Plcg genes constitute a dispersed family.","method":"Interspecific backcross mapping in mice (AEJ/Gn × M. spretus); rodent/human somatic cell hybrid panel mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Strong — genetic mapping in two species with independent methods, independently replicated in subsequent studies","pmids":["7774933"],"is_preprint":false},{"year":2019,"finding":"PLCG2 knockdown in rat liver BRL-3A cells reduces cell viability, proliferation, and G2/M cell cycle progression, with downregulation of NF-κB, FOS, JUN, ELK, BCL2, CCNB1, and CCND1, placing PLCG2 upstream of ERK and NF-κB pathways in hepatocyte proliferation.","method":"siRNA knockdown; MTT and BrdU proliferation assays; flow cytometry cell cycle analysis; qRT-PCR and Western blot for pathway components","journal":"Artificial cells, nanomedicine, and biotechnology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single KD approach, correlative pathway placement without direct mechanistic validation","pmids":["31549850"],"is_preprint":false},{"year":2024,"finding":"DNMT3B methylates the PLCG2 promoter to suppress PLCG2 transcription in colorectal cancer cells; overexpression of PLCG2 inhibits colorectal cancer xenograft tumor growth in vivo.","method":"Methylation-specific PCR; bisulfite-sequencing PCR; qRT-PCR and Western blot; CCK-8 and colony formation assays; in vivo xenograft model","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DNA methylation directly demonstrated at the PLCG2 promoter by MSP/BSP, functional consequences confirmed in vivo, single lab","pmids":["39108206"],"is_preprint":false},{"year":2025,"finding":"PLCG2 interacts with VCP (valosin-containing protein) and promotes mitophagy and cell survival in small cell lung cancer cells; VCP overexpression rescues the inhibitory effects of PLCG2 silencing on mitophagy.","method":"RNA immunoprecipitation; dual-luciferase reporter assay; Western blot for mitophagy markers; CCK-8, colony formation, apoptosis assays; xenograft mouse model","journal":"Anti-cancer drugs","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, interaction demonstrated by RIP but mechanistic link between PLCG2's catalytic function and VCP/mitophagy not established","pmids":["41176779"],"is_preprint":false},{"year":2025,"finding":"In iPSC-derived microglia, the risk-conferring PLCG2-M28L variant reduces TREM2 expression and blunts inflammatory responses while increasing proliferation and cell death, phenotypically resembling PLCG2-knockout microglia; the protective PLCG2-P522R variant shows elevated cytokine secretion after LPS stimulation and resistance to apoptosis, demonstrating allele-specific effects on microglial function.","method":"iPSC-derived microglia with PLCG2P522R, PLCG2M28L, or PLCG2KO; bulk RNA-sequencing; cytokine secretion assays; proliferation and apoptosis assays; TREM2 expression analysis","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic iPSC microglia with multiple functional readouts, single lab","pmids":["41066163"],"is_preprint":false}],"current_model":"PLCG2 encodes phospholipase Cγ2, an enzyme that catalyzes hydrolysis of PIP2 to generate IP3 and DAG; its activity is normally restrained by autoinhibitory SH2 and C2 domains, and is activated downstream of BCR, TREM2, CSF1R, and other immune receptors to trigger Ca2+ release, PKC/PKA activation, NF-κB/NFAT/MAPK signaling, and NLRP3 inflammasome activation—with gain-of-function mutations causing constitutive or temperature-sensitive hyperactivity leading to immune dysregulation, and loss-of-function or haploinsufficiency impairing NK cell calcium flux, neutrophil chemotaxis sensitivity, and microglial responses to amyloid pathology, while a mildly hypermorphic protective variant (P522R) enhances microglial antigen presentation and phagocytic responses associated with reduced Alzheimer's disease risk."},"narrative":{"mechanistic_narrative":"PLCG2 encodes phospholipase Cγ2, a signaling enzyme whose catalytic hydrolysis of phosphoinositides generates IP3 and triggers intracellular Ca2+ release downstream of immune receptors, and whose activity is held in check by an intramolecular autoinhibitory domain [PMID:22236196, PMID:38965708]. The enzyme is normally restrained through contacts between its catalytic core and autoinhibitory regions, including the cSH2 and C2 domains; missense substitutions (S707Y, M1141K, D993Y) and in-frame genomic deletions in these regions relieve autoinhibition to produce constitutive or temperature-sensitive hyperactivity, with the deleted autoinhibitory domain conferring temperature-dependent regulation [PMID:22236196, PMID:23000145, PMID:31853824, PMID:38965708]. Disruption of the catalytic–autoinhibitory interface drives heightened PLCγ2 phosphorylation, elevated IP3, Ca2+ release, and downstream MAPK, NF-κB, and NFAT signaling [PMID:38965708], and the resulting elevated Ca2+ flux engages the NLRP3 inflammasome to drive IL-1β secretion [PMID:25418813]. Gain-of-function variants in PLCG2 cause autoinflammatory and immune-dysregulation disease, while a broad class of monoallelic loss-of-function variants and haploinsufficiency impair NK cell calcium flux and cytotoxicity with relatively preserved B cell function [PMID:37769878, PMID:37714437]. In the immune-receptor pathway, PLCG2 acts downstream of the B cell receptor to drive Ca2+ flux and ERK phosphorylation, and downstream of CSF1R via PKA/UCP2 and PKCε/CREB branches in microglial and neuronal contexts [PMID:31853824, PMID:33101590, PMID:32522286]. PLCG2 is a component of TREM2 signal transduction in microglia, where its expression is induced by amyloid pathology and supports microglial association with plaques; the Alzheimer's-protective P522R variant is mildly hypermorphic and enhances microglial antigen presentation, T cell recruitment, and cytokine responses, whereas risk variants phenocopy PLCG2 loss [PMID:30711010, PMID:40346446, PMID:35142046, PMID:41066163].","teleology":[{"year":2012,"claim":"Established that a discrete region of PLCG2 functions as an autoinhibitory domain whose loss produces constitutive, temperature-sensitive enzyme hyperactivity, defining the regulatory logic of the enzyme.","evidence":"Sequencing of patient cDNA/genomic DNA with enzymatic phospholipase assays and temperature-dependent leukocyte signaling assays","pmids":["22236196"],"confidence":"High","gaps":["Did not resolve the structural basis of the temperature-sensitive conformational switch","Did not map all autoinhibitory contacts within the enzyme"]},{"year":2012,"claim":"Identified the cSH2 domain as a specific autoinhibitory element by showing a single missense substitution there is hypermorphic at physiological temperature, refining which domain restrains activity.","evidence":"Overexpression of mutant in heterologous cells plus ex vivo patient leukocyte signaling and whole-exome sequencing","pmids":["23000145"],"confidence":"High","gaps":["Did not establish the downstream effector consequences of the hypermorphic state","Mechanism of cSH2-mediated autoinhibition not structurally defined"]},{"year":2015,"claim":"Connected PLCγ2 hyperactivity to a defined inflammatory effector by showing elevated Ca2+ drives NLRP3 inflammasome activation and IL-1β secretion, placing PLCG2 upstream of the inflammasome.","evidence":"Caspase-1/IL-1β immunoblotting and FLIPR Ca2+ assays in patient PBMCs with pharmacological PLC, Ca2+, and adenylate cyclase modulation","pmids":["25418813"],"confidence":"High","gaps":["Did not establish whether all GOF variants signal through the same canonical inflammasome route","Molecular link between Ca2+ flux and NLRP3 assembly not detailed"]},{"year":2018,"claim":"Demonstrated that gain-of-function variants can act through inflammasome-independent inflammatory mechanisms, showing the disease pathway is variant-dependent.","evidence":"In vitro PLC activity assay and whole-blood cytokine assays with IL-1 blockade","pmids":["30619256"],"confidence":"Medium","gaps":["Single lab","Alternative inflammatory effector pathway for L848P not identified"]},{"year":2019,"claim":"Extended the autoinhibitory map beyond the SH2 domains by showing a C2-domain GOF variant enhances BCR-triggered Ca2+ and ERK signaling.","evidence":"BCR-triggered Ca2+ flux and ERK phosphorylation by flow cytometry in patient cells and Plcg2-deficient DT40 reconstitution","pmids":["31853824"],"confidence":"Medium","gaps":["Single lab","Structural contribution of C2 domain to autoinhibition not resolved"]},{"year":2019,"claim":"Showed the Alzheimer's-protective P522R variant is a mild gain-of-function allele, linking PLCγ2 enzymatic tuning to reduced disease risk.","evidence":"Radioactive phospholipase, IP-One ELISA, and Ca2+ assays in transfected COS7/HEK293T cells","pmids":["30711010"],"confidence":"High","gaps":["Heterologous system did not establish the cell type relevant to protection","Did not link enzyme activity to a microglial phenotype"]},{"year":2020,"claim":"Placed PLCG2 downstream of CSF1R in microglial/neuronal protective signaling, defining CSF1R/PLCG2/PKA/UCP2 and CSF1R/PLCG2/PKCε/CREB branches.","evidence":"Pharmacological epistasis (BLZ945, U73122) with phospho-pathway immunoblotting and functional readouts in a rat hypoxic-ischemic model","pmids":["33101590","32522286"],"confidence":"Medium","gaps":["Single lab, animal model","Direct PLCγ2 substrate-to-PKA/PKCε link not biochemically demonstrated"]},{"year":2022,"claim":"Positioned PLCG2 within TREM2 signal transduction in microglia and showed its requirement for amyloid-responsive microglial behavior.","evidence":"PLCG2-deficient and TREM2-deficient crosses into 5xFAD mice with bulk RNA-seq, immunostaining, and human transcriptomic correlation","pmids":["40346446"],"confidence":"Medium","gaps":["Directionality of PLCG2-TREM2 regulatory relationship not fully resolved","Single lab"]},{"year":2022,"claim":"Linked the protective P522R allele to a specific microglial gain-of-function — enhanced antigen presentation and T cell engagement — providing a cellular mechanism for AD protection.","evidence":"P522R vs WT iPSC-microglia transplanted into chimeric AD mice with single-cell/bulk RNA-seq and CD8+ T cell histology","pmids":["35142046"],"confidence":"Medium","gaps":["Single lab","Causal link between enzymatic hypermorphism and antigen-presentation phenotype not isolated"]},{"year":2023,"claim":"Systematically classified PLCG2 variants, revealing a dominant class of monoallelic loss-of-function alleles alongside gain-of-function alleles with distinct immune phenotypes including NK cell dysfunction.","evidence":"Mutagenesis and reconstitution in Plcg2-deficient DT40 cells with BCR Ca2+/ERK readouts and primary patient cell assays","pmids":["37769878"],"confidence":"High","gaps":["Mechanistic basis of cell-type-selective phenotypes not resolved","Did not define why NK cells are more sensitive than B cells"]},{"year":2023,"claim":"Established that full PLCG2 gene dosage is specifically required for NK cell function, showing haploinsufficiency causes NK immunodeficiency with preserved B cells.","evidence":"Whole-exome sequencing, mass cytometry, NK cytotoxicity/Ca2+ assays, and a Plcg2+/- mouse phenocopy","pmids":["37714437"],"confidence":"High","gaps":["Molecular basis for NK-specific dosage sensitivity not identified"]},{"year":2024,"claim":"Provided direct biochemical evidence that autoinhibition operates through a catalytic–autoinhibitory domain interaction, disrupted by D993Y to drive Ca2+/MAPK/NF-κB/NFAT signaling.","evidence":"IP3 ELISA, Ca2+ flux, phospho-immunoblotting, NF-κB/NFAT luciferase reporters, and co-immunoprecipitation of domain interaction across HEK293T/COS-7/PLCG2-KO THP-1 cells","pmids":["38965708"],"confidence":"High","gaps":["Structural detail of the interdomain interface not solved","Did not test whether other GOF variants disrupt the same contact"]},{"year":2024,"claim":"Demonstrated a dominant-negative class of PLCG2 alleles, where in-frame deletion proteins fail to transmit BCR signaling, expanding the spectrum of pathogenic mechanisms beyond simple GOF/LOF.","evidence":"cDNA/whole-genome sequencing and reconstitution of deletion transcripts in Plcg2-deficient DT40 cells with BCR-triggered ERK readout","pmids":["39667583"],"confidence":"Medium","gaps":["Single lab","Mechanism by which deletion protein interferes with wild-type enzyme not defined"]},{"year":2024,"claim":"Identified epigenetic silencing of PLCG2 in cancer and a tumor-suppressive role, broadening its functional contexts beyond immune signaling.","evidence":"Methylation-specific/bisulfite PCR linking DNMT3B to PLCG2 promoter methylation, with xenograft tumor growth assays","pmids":["39108206"],"confidence":"Medium","gaps":["Single lab","Effector pathway downstream of PLCG2 in colorectal cancer not defined"]},{"year":2025,"claim":"Defined a chemotaxis-gating function for PLCγ2 in neutrophils via control of CAPRI membrane recruitment and Ras/PI3Kγ activity.","evidence":"Ca2+ imaging, CAPRI membrane localization, Ras/PI3Kγ activity, actin and chemotaxis assays in plcg2-knockdown neutrophils (preprint)","pmids":["bio_10.1101_2025.04.07.647573"],"confidence":"Medium","gaps":["Preprint, single lab","Direct PLCγ2-CAPRI biochemical link not established"]},{"year":2025,"claim":"Identified splice-based loss-of-function mechanisms, including an NMD-susceptible isoform lacking the Ca2+-binding domain generated by a risk allele.","evidence":"Minigene splicing in BV-2 cells, cycloheximide NMD assessment, and Ca2+ response comparison in transfected HEK293 cells","pmids":["41459197"],"confidence":"Medium","gaps":["Single lab","Endogenous in vivo abundance of the isoform not quantified"]},{"year":2025,"claim":"Resolved allele-specific microglial consequences, with risk M28L phenocopying PLCG2 knockout and protective P522R enhancing cytokine responses and apoptosis resistance.","evidence":"Isogenic iPSC-derived microglia (P522R/M28L/KO) with bulk RNA-seq, cytokine, proliferation, apoptosis, and TREM2 expression assays","pmids":["41066163"],"confidence":"Medium","gaps":["Single lab","Mechanism connecting M28L to TREM2 downregulation not defined"]},{"year":null,"claim":"How PLCγ2 dosage and activity translate into cell-type-selective phenotypes (NK vs B cells, microglia vs neurons) and the structural basis of its temperature-sensitive autoinhibition remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of the autoinhibited and activated states reported in the corpus","Cell-type-specific effector wiring not mechanistically dissected","Neuronal role of PLCG2 rests on preprint-level evidence"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,3,13]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[13]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,7,8,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,11,12,9]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,13]}],"complexes":[],"partners":["TREM2","CSF1R","VCP","CAPRI"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P16885","full_name":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2","aliases":["Phosphoinositide phospholipase C-gamma-2","Phospholipase C-IV","PLC-IV","Phospholipase C-gamma-2","PLC-gamma-2"],"length_aa":1265,"mass_kda":147.9,"function":"The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signaling","subcellular_location":"Membrane raft","url":"https://www.uniprot.org/uniprotkb/P16885/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLCG2","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLCG2","total_profiled":1310},"omim":[{"mim_id":"614878","title":"AUTOINFLAMMATION, ANTIBODY DEFICIENCY, AND IMMUNE DYSREGULATION; APLAID","url":"https://www.omim.org/entry/614878"},{"mim_id":"614468","title":"FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3","url":"https://www.omim.org/entry/614468"},{"mim_id":"609201","title":"UBIQUITIN-ASSOCIATED AND SH3 DOMAIN-CONTAINING PROTEIN B; UBASH3B","url":"https://www.omim.org/entry/609201"},{"mim_id":"608462","title":"HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 8; HSCR8","url":"https://www.omim.org/entry/608462"},{"mim_id":"607360","title":"LACRITIN; LACRT","url":"https://www.omim.org/entry/607360"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":42.3}],"url":"https://www.proteinatlas.org/search/PLCG2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P16885","domains":[{"cath_id":"2.30.29.30","chopping":"8-136","consensus_level":"high","plddt":88.9508,"start":8,"end":136},{"cath_id":"1.10.238,1.10.238","chopping":"142-222","consensus_level":"medium","plddt":88.0731,"start":142,"end":222},{"cath_id":"1.10.238.10","chopping":"228-300","consensus_level":"medium","plddt":83.2322,"start":228,"end":300},{"cath_id":"3.20.20.190","chopping":"319-465_927-1045","consensus_level":"medium","plddt":91.0571,"start":319,"end":1045},{"cath_id":"2.30.29.30","chopping":"478-512_845-895","consensus_level":"high","plddt":80.0397,"start":478,"end":895},{"cath_id":"3.30.505.10","chopping":"533-630","consensus_level":"high","plddt":84.5373,"start":533,"end":630},{"cath_id":"3.30.505.10","chopping":"648-732","consensus_level":"high","plddt":84.8684,"start":648,"end":732},{"cath_id":"2.30.30.40","chopping":"775-827","consensus_level":"high","plddt":86.3191,"start":775,"end":827},{"cath_id":"2.60.40.150","chopping":"1055-1189","consensus_level":"medium","plddt":89.9519,"start":1055,"end":1189},{"cath_id":"1.10.287","chopping":"1194-1264","consensus_level":"medium","plddt":72.8723,"start":1194,"end":1264}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16885","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16885-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16885-F1-predicted_aligned_error_v6.png","plddt_mean":83.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLCG2","jax_strain_url":"https://www.jax.org/strain/search?query=PLCG2"},"sequence":{"accession":"P16885","fasta_url":"https://rest.uniprot.org/uniprotkb/P16885.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16885/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16885"}},"corpus_meta":[{"pmid":"28714976","id":"PMC_28714976","title":"Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.","date":"2017","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28714976","citation_count":778,"is_preprint":false},{"pmid":"22236196","id":"PMC_22236196","title":"Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22236196","citation_count":307,"is_preprint":false},{"pmid":"23000145","id":"PMC_23000145","title":"A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23000145","citation_count":268,"is_preprint":false},{"pmid":"30711010","id":"PMC_30711010","title":"Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.","date":"2019","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30711010","citation_count":112,"is_preprint":false},{"pmid":"31243043","id":"PMC_31243043","title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31243043","citation_count":109,"is_preprint":false},{"pmid":"25349203","id":"PMC_25349203","title":"HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome.","date":"2014","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/25349203","citation_count":107,"is_preprint":false},{"pmid":"31131421","id":"PMC_31131421","title":"A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31131421","citation_count":94,"is_preprint":false},{"pmid":"30326945","id":"PMC_30326945","title":"ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans.","date":"2018","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/30326945","citation_count":81,"is_preprint":false},{"pmid":"35180881","id":"PMC_35180881","title":"PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer's disease.","date":"2022","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35180881","citation_count":75,"is_preprint":false},{"pmid":"36696464","id":"PMC_36696464","title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36696464","citation_count":67,"is_preprint":false},{"pmid":"25418813","id":"PMC_25418813","title":"Connecting two pathways through Ca 2+ signaling: NLRP3 inflammasome activation induced by a hypermorphic PLCG2 mutation.","date":"2015","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25418813","citation_count":66,"is_preprint":false},{"pmid":"30619256","id":"PMC_30619256","title":"Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30619256","citation_count":54,"is_preprint":false},{"pmid":"32166339","id":"PMC_32166339","title":"PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment.","date":"2020","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/32166339","citation_count":46,"is_preprint":false},{"pmid":"25760457","id":"PMC_25760457","title":"Distinct Cutaneous Manifestations and Cold-Induced Leukocyte Activation Associated With PLCG2 Mutations.","date":"2015","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25760457","citation_count":45,"is_preprint":false},{"pmid":"37769878","id":"PMC_37769878","title":"PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37769878","citation_count":43,"is_preprint":false},{"pmid":"37955424","id":"PMC_37955424","title":"Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/37955424","citation_count":43,"is_preprint":false},{"pmid":"35142046","id":"PMC_35142046","title":"The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model.","date":"2022","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/35142046","citation_count":42,"is_preprint":false},{"pmid":"37031207","id":"PMC_37031207","title":"PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37031207","citation_count":41,"is_preprint":false},{"pmid":"32671674","id":"PMC_32671674","title":"Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations.","date":"2020","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32671674","citation_count":40,"is_preprint":false},{"pmid":"33101590","id":"PMC_33101590","title":"Rh-CSF1 Attenuates Oxidative Stress and Neuronal Apoptosis via the CSF1R/PLCG2/PKA/UCP2 Signaling Pathway in a Rat Model of Neonatal HIE.","date":"2020","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/33101590","citation_count":31,"is_preprint":false},{"pmid":"32894242","id":"PMC_32894242","title":"Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes.","date":"2020","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/32894242","citation_count":31,"is_preprint":false},{"pmid":"31853824","id":"PMC_31853824","title":"A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31853824","citation_count":29,"is_preprint":false},{"pmid":"29538758","id":"PMC_29538758","title":"Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1.","date":"2018","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29538758","citation_count":26,"is_preprint":false},{"pmid":"32522286","id":"PMC_32522286","title":"Rh-CSF1 attenuates neuroinflammation via the CSF1R/PLCG2/PKCε pathway in a rat model of neonatal HIE.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32522286","citation_count":24,"is_preprint":false},{"pmid":"39494327","id":"PMC_39494327","title":"Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39494327","citation_count":21,"is_preprint":false},{"pmid":"35813947","id":"PMC_35813947","title":"Plcg2 Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer's Disease-Relevant Phenotypes in Mice.","date":"2022","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35813947","citation_count":21,"is_preprint":false},{"pmid":"31549850","id":"PMC_31549850","title":"PLCG2 promotes hepatocyte proliferation in vitro via NF-κB and ERK pathway by targeting bcl2, myc and ccnd1.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31549850","citation_count":20,"is_preprint":false},{"pmid":"33725976","id":"PMC_33725976","title":"PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma.","date":"2021","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33725976","citation_count":18,"is_preprint":false},{"pmid":"36530083","id":"PMC_36530083","title":"Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease.","date":"2023","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/36530083","citation_count":17,"is_preprint":false},{"pmid":"7774933","id":"PMC_7774933","title":"Phospholipase C gamma-2 (Plcg2) and phospholipase C gamma-1 (Plcg1) map to distinct regions in the human and mouse genomes.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7774933","citation_count":15,"is_preprint":false},{"pmid":"39108206","id":"PMC_39108206","title":"Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2.","date":"2024","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/39108206","citation_count":11,"is_preprint":false},{"pmid":"26966907","id":"PMC_26966907","title":"A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26966907","citation_count":10,"is_preprint":false},{"pmid":"35955991","id":"PMC_35955991","title":"Variant in the PLCG2 Gene May Cause a Phenotypic Overlap of APLAID/PLAID: Case Series and Literature Review.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35955991","citation_count":10,"is_preprint":false},{"pmid":"32014489","id":"PMC_32014489","title":"A new report of autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID) with a homozygous pattern from Iran.","date":"2020","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32014489","citation_count":10,"is_preprint":false},{"pmid":"31560769","id":"PMC_31560769","title":"Pathway Analysis Integrating Genome-Wide and Functional Data Identifies PLCG2 as a Candidate Gene for Age-Related Macular Degeneration.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31560769","citation_count":9,"is_preprint":false},{"pmid":"33936634","id":"PMC_33936634","title":"Four diseases, PLAID, APLAID, FCAS3 and CVID and one gene (PHOSPHOLIPASE C, GAMMA-2; PLCG2): Striking clinical phenotypic overlap and difference.","date":"2021","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/33936634","citation_count":9,"is_preprint":false},{"pmid":"37714437","id":"PMC_37714437","title":"Human PLCG2 haploinsufficiency results in a novel natural killer cell immunodeficiency.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37714437","citation_count":8,"is_preprint":false},{"pmid":"40346446","id":"PMC_40346446","title":"PLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/40346446","citation_count":7,"is_preprint":false},{"pmid":"39487477","id":"PMC_39487477","title":"Alzheimer's disease-associated protective variant Plcg2-P522R modulates peripheral macrophage function in a sex-dimorphic manner.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39487477","citation_count":7,"is_preprint":false},{"pmid":"39614428","id":"PMC_39614428","title":"The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma.","date":"2024","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/39614428","citation_count":6,"is_preprint":false},{"pmid":"34768012","id":"PMC_34768012","title":"A novel likely pathogenic PLCG2 variant in a patient with a recurrent skin blistering disease and B-cell lymphopenia.","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34768012","citation_count":6,"is_preprint":false},{"pmid":"39863641","id":"PMC_39863641","title":"Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39863641","citation_count":5,"is_preprint":false},{"pmid":"36776842","id":"PMC_36776842","title":"Clinical and immunological features of an APLAID patient caused by a novel mutation in PLCG2.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36776842","citation_count":4,"is_preprint":false},{"pmid":"38965708","id":"PMC_38965708","title":"Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.","date":"2024","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/38965708","citation_count":2,"is_preprint":false},{"pmid":"39667583","id":"PMC_39667583","title":"Splice site and de novo variants can cause PLCG2-associated immune dysregulation with cold urticaria.","date":"2024","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39667583","citation_count":2,"is_preprint":false},{"pmid":"41066163","id":"PMC_41066163","title":"Alzheimer's disease-associated PLCG2 variants alter microglial state and function in human induced pluripotent stem cell-derived microglia-like cells.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/41066163","citation_count":2,"is_preprint":false},{"pmid":"27323081","id":"PMC_27323081","title":"Construction of recombinant adenovirus Ad-rat PLCg2-shRNA and successful suppression of PLCg2 expression in BRL-3A cells.","date":"2016","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/27323081","citation_count":2,"is_preprint":false},{"pmid":"31955222","id":"PMC_31955222","title":"Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.","date":"2020","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31955222","citation_count":2,"is_preprint":false},{"pmid":"39197752","id":"PMC_39197752","title":"PLCG2 variants in cherubism.","date":"2024","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39197752","citation_count":1,"is_preprint":false},{"pmid":"40170866","id":"PMC_40170866","title":"Case Report: de novo in-frame deletion in PLCG2 gene: a case report of B-cell lymphopenia, pulmonary bullae, and cutis laxa.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40170866","citation_count":1,"is_preprint":false},{"pmid":"41928929","id":"PMC_41928929","title":"Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41928929","citation_count":1,"is_preprint":false},{"pmid":"33089525","id":"PMC_33089525","title":"A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.","date":"2020","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/33089525","citation_count":1,"is_preprint":false},{"pmid":"40585241","id":"PMC_40585241","title":"Genetics of PLCG2 expression and splicing relative to Alzheimer's disease risk.","date":"2025","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/40585241","citation_count":0,"is_preprint":false},{"pmid":"41459197","id":"PMC_41459197","title":"Genetics of PLCG2 expression and splicing relative to Alzheimer's disease risk.","date":"2025","source":"Molecular neurodegeneration advances","url":"https://pubmed.ncbi.nlm.nih.gov/41459197","citation_count":0,"is_preprint":false},{"pmid":"41888907","id":"PMC_41888907","title":"PLCG2 signaling and genetic resilience in Alzheimer's disease.","date":"2026","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/41888907","citation_count":0,"is_preprint":false},{"pmid":"41507916","id":"PMC_41507916","title":"PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications.","date":"2026","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41507916","citation_count":0,"is_preprint":false},{"pmid":"41176779","id":"PMC_41176779","title":"PLCG2 promotes cell survival and mitophagy of small cell lung cancer via regulating VCP.","date":"2025","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/41176779","citation_count":0,"is_preprint":false},{"pmid":"38562814","id":"PMC_38562814","title":"Splice site and de novo mutations can cause mixed dominant negative/gain of function PLCG2-associated immune dysregulation with cold urticaria (CU-PLAID).","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38562814","citation_count":0,"is_preprint":false},{"pmid":"42138601","id":"PMC_42138601","title":"Potentially Functional Variants in FCER1A and PLCG2, Two B Cell-Related Immune Genes Predict the Survival of Chinese Gastric Cancer Patients.","date":"2026","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/42138601","citation_count":0,"is_preprint":false},{"pmid":"41537131","id":"PMC_41537131","title":"Early-onset bibasilar emphysema in a patient with PLCG2-related immune dysregulation.","date":"2025","source":"Respiratory medicine case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41537131","citation_count":0,"is_preprint":false},{"pmid":"41620758","id":"PMC_41620758","title":"Protective PLCG2 variants associate with a delayed onset of Alzheimer's disease among heterozygous APOE ε4 carriers.","date":"2026","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41620758","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.22.25336304","title":"The protective <i>PLCG2</i> variants delay Alzheimer’s disease onset age in <i>APOE ε</i>4 carriers","date":"2025-09-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.22.25336304","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.05.25339630","title":"Cerebrospinal fluid transcriptional immune pathways linked to survival in HIV-associated tuberculous meningitis","date":"2025-11-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.05.25339630","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.07.647573","title":"PLCγ2 Controls Neutrophil Sensitivity through Calcium Oscillation and Gates Chemoattractant Concentration Range for Chemotaxis","date":"2025-04-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.07.647573","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.11.659052","title":"A collection of patient-derived intestinal organoid lines reveals epithelial pheno-types associated with genetic drivers of pediatric inflammatory bowel disease","date":"2025-06-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.11.659052","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.26.24316189","title":"Integrating explainable machine learning and transcriptomics data reveals cell-type specific immune signatures underlying macular degeneration","date":"2024-10-27","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.26.24316189","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39451,"output_tokens":6157,"usd":0.105354,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14917,"output_tokens":5242,"usd":0.102818,"stage2_stop_reason":"end_turn"},"total_usd":0.208172,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"In-frame genomic deletions within the autoinhibitory domain of PLCG2 result in protein products with constitutive phospholipase activity. Cells expressing these deletion proteins show diminished cellular signaling at 37°C but enhanced signaling at subphysiologic temperatures, establishing that the deleted region encodes an autoinhibitory domain critical for temperature-dependent regulation.\",\n      \"method\": \"Sequencing of cDNA and genomic DNA from patients; enzymatic assays measuring phospholipase activity; flow cytometry-based signaling assays in patient leukocytes at different temperatures\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — enzymatic activity directly measured, multiple orthogonal methods (genetic, biochemical, functional cell assays), replicated across three families with distinct deletions\",\n      \"pmids\": [\"22236196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The p.Ser707Tyr missense substitution in the autoinhibitory cSH2 domain of PLCγ2 causes enhanced PLCγ2 activity (hypermorphic effect) with increased intracellular signaling at physiological temperatures, establishing that the cSH2 domain normally restrains enzyme activity.\",\n      \"method\": \"Overexpression of altered protein in heterologous cells; ex vivo leukocyte signaling assays from affected patients; whole-exome sequencing to identify the de novo variant\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal confirmation by overexpression and ex vivo patient cell assays, independent replication in subsequent studies\",\n      \"pmids\": [\"23000145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The hypermorphic p.Ser707Tyr PLCγ2 mutation causes elevated basal intracellular Ca2+ and enhanced Ca2+ flux, which drives NLRP3 inflammasome activation and IL-1β secretion in response to LPS alone; this effect is blocked by PLC inhibitors, intracellular Ca2+ blockers, or adenylate cyclase activators, placing PLCG2 upstream of the NLRP3 inflammasome via Ca2+ signaling.\",\n      \"method\": \"Western blotting for caspase-1 cleavage and IL-1β; FLIPR calcium flux assay in patient PBMCs; pharmacological inhibition with U73122 (PLC inhibitor), Ca2+ blockers, and forskolin\",\n      \"journal\": \"Arthritis & rheumatology (Hoboken, N.J.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal pharmacological interventions and biochemical readouts in primary patient cells, consistent with overexpression studies in the original report\",\n      \"pmids\": [\"25418813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The Alzheimer's disease-protective p.P522R variant of PLCG2 produces a small hypermorphic (gain-of-function) effect on enzyme activity, as measured by multiple orthogonal assays in transfected heterologous cells.\",\n      \"method\": \"Radioactive phospholipase assay; IP-One ELISA; calcium assay in transfected COS7 and HEK293T cells\",\n      \"journal\": \"Alzheimer's research & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — three independent orthogonal enzymatic assays in heterologous expression system confirming the same hypermorphic conclusion\",\n      \"pmids\": [\"30711010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The p.Met1141Lys gain-of-function mutation in the C2 domain of PLCγ2 causes increased B cell receptor-triggered calcium influx and ERK phosphorylation, as demonstrated in primary patient cells and by overexpression in a PLCγ2-knockout DT40 cell line, expanding the functional domains required for autoinhibition beyond the SH2 domains.\",\n      \"method\": \"BCR-triggered calcium flux and ERK phosphorylation assays by flow cytometry in primary cells; overexpression of mutant in Plcg2-deficient DT40 B cells\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal validation in knockout cell line plus primary patient cells, single lab\",\n      \"pmids\": [\"31853824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A novel p.L848P missense mutation in PLCG2 causes increased basal and EGF-stimulated PLCγ2 activity in vitro, establishing this as a gain-of-function variant; unlike S707Y, it does not appear to activate the NLRP3 inflammasome as the primary inflammatory mechanism.\",\n      \"method\": \"In vitro PLC activity assay; whole blood cytokine assays; negative result for IL-1β response to IL-1 blockade\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzymatic assay plus ex vivo functional cytokine assay, single lab\",\n      \"pmids\": [\"30619256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Two novel PLCG2 variants (p.Ala708Pro and p.Leu845_Leu848del) cause enhanced PLCγ2 enzymatic activity as measured by ex vivo calcium responses in patient B cells stimulated via IgM and by in vitro PLC activity assays; additionally, both variants activate the NLRP3 inflammasome through the alternative rather than the canonical pathway.\",\n      \"method\": \"Ex vivo calcium flux assay in patient B cells; in vitro PLC activity assay; Western blotting for inflammasome components\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal assays (calcium flux and enzymatic assay), single lab\",\n      \"pmids\": [\"32671674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CSF1R activation by rh-CSF1 increases phosphorylation of PLCG2, and pharmacological inhibition of PLCG2 (U73122) abolishes neuroprotective effects of rh-CSF1 in a rat hypoxic-ischemic model, placing PLCG2 downstream of CSF1R in a CSF1R/PLCG2/PKA/UCP2 signaling pathway that reduces oxidative stress and neuronal apoptosis.\",\n      \"method\": \"Western blot for p-PLCG2, p-PKA, UCP2; pharmacological inhibition with CSF1R inhibitor BLZ945 and PLCG2 inhibitor U73122; brain infarct volume, TUNEL staining, immunofluorescence in rat pups\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement by pharmacological epistasis with two inhibitors, multiple functional readouts, single lab, animal model\",\n      \"pmids\": [\"33101590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CSF1R activation by rh-CSF1 increases p-PLCG2, p-PKCε, and p-CREB; inhibition of PLCG2 by U73122 abolishes anti-inflammatory effects, establishing a CSF1R/PLCG2/PKCε/CREB signaling pathway downstream of CSF1R in microglial neuroinflammation regulation.\",\n      \"method\": \"Western blot for pathway components; pharmacological inhibition with BLZ945 and U73122; brain edema, infarct area, and cytokine measurements in rat HIE model\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological epistasis with two inhibitors, multiple biochemical readouts, single lab, animal model\",\n      \"pmids\": [\"32522286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PLCG2 deficiency in 5xFAD mice abolishes the increase in Plcg2 expression driven by amyloid pathology, reduces microglial association with amyloid plaques, and perturbs immune-related transcriptional pathways; PLCG2 deficiency also reduces TREM2 expression, while TREM2 deficiency increases PLCG2 expression, placing PLCG2 as a component of TREM2 signal transduction that may play an upstream regulatory role.\",\n      \"method\": \"PLCG2-deficient × 5xFAD mouse crosses; TREM2-deficient × 5xFAD crosses; bulk RNA-sequencing transcriptomics; immunostaining; correlation with human bulk RNA-seq data\",\n      \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout mouse model with transcriptomic and histological readouts, single lab, corroborated by human transcriptomics\",\n      \"pmids\": [\"40346446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PLCG2 P522R variant in human iPSC-derived microglia transplanted into chimeric AD mice induces increased HLA/antigen presentation gene expression, chemokine signaling, and T cell proliferation pathways, and promotes CD8+ T cell recruitment to the brain, demonstrating a functional role for PLCG2 in microglial antigen presentation and T cell engagement.\",\n      \"method\": \"iPSC-derived microglia (P522R vs. wild-type) transplanted into chimeric AD mice; single-cell and bulk RNA-sequencing; histological analysis of CD8+ T cell infiltration\",\n      \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — iPSC microglia chimeric mouse model with single-cell transcriptomics and histology, single lab\",\n      \"pmids\": [\"35142046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Functional classification of numerous PLCG2 variants in Plcg2-deficient DT40 B cells revealed that most functional variants define a class of monoallelic loss-of-function (LOF) mutations, while 13 variants are gain-of-function (GOF); LOF and GOF variants cause overlapping but distinct immune phenotypes, including NK cell dysfunction that can exceed B cell effects.\",\n      \"method\": \"Mutagenesis of EGFP-PLCG2 plasmid; overexpression in Plcg2-deficient DT40 cells; BCR-induced calcium flux and ERK phosphorylation by flow cytometry; primary patient cell calcium flux assays\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — systematic mutagenesis plus two orthogonal functional readouts across large variant set in defined knockout cell line, corroborated by primary patient cells\",\n      \"pmids\": [\"37769878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PLCG2 haploinsufficiency (heterozygous loss-of-function) causes impaired NK cell calcium flux and cytotoxicity with preserved B cell function; Plcg2+/- mice phenocopy this human NK cell immunodeficiency, establishing that full PLCG2 dosage is required for normal NK cell—but not B cell—function.\",\n      \"method\": \"Whole-exome sequencing; mass cytometry; functional NK cell cytotoxicity assays; calcium flux assays; Plcg2+/- mouse model\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetic variants validated functionally in primary cells and phenocopied in a mouse model, multiple orthogonal methods\",\n      \"pmids\": [\"37714437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The PLCG2 p.D993Y variant disrupts the interaction between catalytic and autoinhibitory domains of PLCγ2, causing autoactivation with heightened PLCγ2 phosphorylation, elevated IP3 production, intracellular Ca2+ release, and activation of MAPK, NF-κB, and NFAT signaling pathways.\",\n      \"method\": \"IP3 (inositol monophosphate) ELISA; calcium flux assay; immunoblotting for pPLCγ2; luciferase reporter assays for NF-κB/NFAT; immunoprecipitation for domain interaction; expression in HEK293T, COS-7, and PLCG2-KO THP-1 cells\",\n      \"journal\": \"Arthritis & rheumatology (Hoboken, N.J.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal biochemical assays including immunoprecipitation for domain interaction plus functional signaling readouts in multiple cell lines\",\n      \"pmids\": [\"38965708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In-frame deletions of exons 18-19 or 19-22 in PLCG2 (caused by splice site or de novo mutations) produce proteins that fail to phosphorylate ERK in response to B cell receptor crosslinking at physiological conditions, consistent with dominant-negative function.\",\n      \"method\": \"cDNA sequencing of full-length PLCG2; whole genome sequencing; overexpression of deletion transcripts in Plcg2-deficient DT40 cells; ERK phosphorylation by flow cytometry with/without BCR crosslinking\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional validation in Plcg2-KO cell line with BCR stimulation, single lab, multiple variant confirmations\",\n      \"pmids\": [\"39667583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLCG2 downregulation in neurons (non-microglial) disrupts dendritic morphology, impairs synaptic function, and increases Aβ levels and tau phosphorylation in rat primary neuronal cultures and human neuronal cultures; a loss-of-function PLCG2 variant (R953*) recapitulates these synaptic and AD-related phenotypes, suggesting a neuronal role for PLCG2 in synaptic maintenance.\",\n      \"method\": \"High-content screening in rat primary neuronal cultures; PLCG2 knockdown; human neuronal culture experiments; Aβ measurement; tau phosphorylation assay; single-nuclei RNA-seq\",\n      \"journal\": \"bioRxiv : the preprint server for biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — novel mechanistic findings in neuronal cells with multiple readouts, but preprint, single lab, no replication\",\n      \"pmids\": [\"41928929\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLCγ2 mediates spontaneous calcium oscillation in neutrophils and contributes to chemoattractant-triggered calcium response; PLCγ2-deficient (plcg2 kd) neutrophils show impaired Ca2+ oscillation, decreased membrane targeting of the RasGAP CAPRI, and increased Ras/PI3Kγ activation and actin polymerization, demonstrating that PLCγ2 gates chemoattractant concentration range for chemotaxis by controlling CAPRI membrane recruitment.\",\n      \"method\": \"Ca2+ imaging; membrane localization assays for CAPRI; Ras activation assay; PI3Kγ activity; actin polymerization assay; chemotaxis assay in plcg2 knockdown neutrophils\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays in KD neutrophils establishing pathway placement, but preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.04.07.647573\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A PLCG2 splice isoform lacking 65 bp from exon 28 (D65-PLCG2), generated by the rs1071644-T allele, lacks the Ca2+-binding domain and does not respond to cytosolic Ca2+ increase in the same manner as canonical PLCG2; D65-PLCG2 is susceptible to nonsense-mediated RNA decay, representing a loss-of-function mechanism.\",\n      \"method\": \"Minigene splicing assay in BV-2 microglial cells; cycloheximide treatment for NMD assessment; Ca2+ response assay comparing D65-PLCG2-GFP vs. PLCG2-GFP in transfected HEK293 cells; qRT-PCR\",\n      \"journal\": \"Molecular neurodegeneration advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — functional assay in transfected cells with minigene validation and NMD assessment, single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"41459197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"PLCG2 maps to the long arm of human chromosome 16 (region q22-qter) and to the central region of mouse chromosome 8, distinct from the chromosomal location of the paralog PLCG1, establishing that the mammalian Plcg genes constitute a dispersed family.\",\n      \"method\": \"Interspecific backcross mapping in mice (AEJ/Gn × M. spretus); rodent/human somatic cell hybrid panel mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic mapping in two species with independent methods, independently replicated in subsequent studies\",\n      \"pmids\": [\"7774933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PLCG2 knockdown in rat liver BRL-3A cells reduces cell viability, proliferation, and G2/M cell cycle progression, with downregulation of NF-κB, FOS, JUN, ELK, BCL2, CCNB1, and CCND1, placing PLCG2 upstream of ERK and NF-κB pathways in hepatocyte proliferation.\",\n      \"method\": \"siRNA knockdown; MTT and BrdU proliferation assays; flow cytometry cell cycle analysis; qRT-PCR and Western blot for pathway components\",\n      \"journal\": \"Artificial cells, nanomedicine, and biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single KD approach, correlative pathway placement without direct mechanistic validation\",\n      \"pmids\": [\"31549850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DNMT3B methylates the PLCG2 promoter to suppress PLCG2 transcription in colorectal cancer cells; overexpression of PLCG2 inhibits colorectal cancer xenograft tumor growth in vivo.\",\n      \"method\": \"Methylation-specific PCR; bisulfite-sequencing PCR; qRT-PCR and Western blot; CCK-8 and colony formation assays; in vivo xenograft model\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DNA methylation directly demonstrated at the PLCG2 promoter by MSP/BSP, functional consequences confirmed in vivo, single lab\",\n      \"pmids\": [\"39108206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLCG2 interacts with VCP (valosin-containing protein) and promotes mitophagy and cell survival in small cell lung cancer cells; VCP overexpression rescues the inhibitory effects of PLCG2 silencing on mitophagy.\",\n      \"method\": \"RNA immunoprecipitation; dual-luciferase reporter assay; Western blot for mitophagy markers; CCK-8, colony formation, apoptosis assays; xenograft mouse model\",\n      \"journal\": \"Anti-cancer drugs\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, interaction demonstrated by RIP but mechanistic link between PLCG2's catalytic function and VCP/mitophagy not established\",\n      \"pmids\": [\"41176779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In iPSC-derived microglia, the risk-conferring PLCG2-M28L variant reduces TREM2 expression and blunts inflammatory responses while increasing proliferation and cell death, phenotypically resembling PLCG2-knockout microglia; the protective PLCG2-P522R variant shows elevated cytokine secretion after LPS stimulation and resistance to apoptosis, demonstrating allele-specific effects on microglial function.\",\n      \"method\": \"iPSC-derived microglia with PLCG2P522R, PLCG2M28L, or PLCG2KO; bulk RNA-sequencing; cytokine secretion assays; proliferation and apoptosis assays; TREM2 expression analysis\",\n      \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic iPSC microglia with multiple functional readouts, single lab\",\n      \"pmids\": [\"41066163\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLCG2 encodes phospholipase Cγ2, an enzyme that catalyzes hydrolysis of PIP2 to generate IP3 and DAG; its activity is normally restrained by autoinhibitory SH2 and C2 domains, and is activated downstream of BCR, TREM2, CSF1R, and other immune receptors to trigger Ca2+ release, PKC/PKA activation, NF-κB/NFAT/MAPK signaling, and NLRP3 inflammasome activation—with gain-of-function mutations causing constitutive or temperature-sensitive hyperactivity leading to immune dysregulation, and loss-of-function or haploinsufficiency impairing NK cell calcium flux, neutrophil chemotaxis sensitivity, and microglial responses to amyloid pathology, while a mildly hypermorphic protective variant (P522R) enhances microglial antigen presentation and phagocytic responses associated with reduced Alzheimer's disease risk.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PLCG2 encodes phospholipase Cγ2, a signaling enzyme whose catalytic hydrolysis of phosphoinositides generates IP3 and triggers intracellular Ca2+ release downstream of immune receptors, and whose activity is held in check by an intramolecular autoinhibitory domain [#0, #13]. The enzyme is normally restrained through contacts between its catalytic core and autoinhibitory regions, including the cSH2 and C2 domains; missense substitutions (S707Y, M1141K, D993Y) and in-frame genomic deletions in these regions relieve autoinhibition to produce constitutive or temperature-sensitive hyperactivity, with the deleted autoinhibitory domain conferring temperature-dependent regulation [#0, #1, #4, #13]. Disruption of the catalytic–autoinhibitory interface drives heightened PLCγ2 phosphorylation, elevated IP3, Ca2+ release, and downstream MAPK, NF-κB, and NFAT signaling [#13], and the resulting elevated Ca2+ flux engages the NLRP3 inflammasome to drive IL-1β secretion [#2]. Gain-of-function variants in PLCG2 cause autoinflammatory and immune-dysregulation disease, while a broad class of monoallelic loss-of-function variants and haploinsufficiency impair NK cell calcium flux and cytotoxicity with relatively preserved B cell function [#11, #12]. In the immune-receptor pathway, PLCG2 acts downstream of the B cell receptor to drive Ca2+ flux and ERK phosphorylation, and downstream of CSF1R via PKA/UCP2 and PKCε/CREB branches in microglial and neuronal contexts [#4, #7, #8]. PLCG2 is a component of TREM2 signal transduction in microglia, where its expression is induced by amyloid pathology and supports microglial association with plaques; the Alzheimer's-protective P522R variant is mildly hypermorphic and enhances microglial antigen presentation, T cell recruitment, and cytokine responses, whereas risk variants phenocopy PLCG2 loss [#3, #9, #10, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that a discrete region of PLCG2 functions as an autoinhibitory domain whose loss produces constitutive, temperature-sensitive enzyme hyperactivity, defining the regulatory logic of the enzyme.\",\n      \"evidence\": \"Sequencing of patient cDNA/genomic DNA with enzymatic phospholipase assays and temperature-dependent leukocyte signaling assays\",\n      \"pmids\": [\"22236196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of the temperature-sensitive conformational switch\", \"Did not map all autoinhibitory contacts within the enzyme\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified the cSH2 domain as a specific autoinhibitory element by showing a single missense substitution there is hypermorphic at physiological temperature, refining which domain restrains activity.\",\n      \"evidence\": \"Overexpression of mutant in heterologous cells plus ex vivo patient leukocyte signaling and whole-exome sequencing\",\n      \"pmids\": [\"23000145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the downstream effector consequences of the hypermorphic state\", \"Mechanism of cSH2-mediated autoinhibition not structurally defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected PLCγ2 hyperactivity to a defined inflammatory effector by showing elevated Ca2+ drives NLRP3 inflammasome activation and IL-1β secretion, placing PLCG2 upstream of the inflammasome.\",\n      \"evidence\": \"Caspase-1/IL-1β immunoblotting and FLIPR Ca2+ assays in patient PBMCs with pharmacological PLC, Ca2+, and adenylate cyclase modulation\",\n      \"pmids\": [\"25418813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether all GOF variants signal through the same canonical inflammasome route\", \"Molecular link between Ca2+ flux and NLRP3 assembly not detailed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that gain-of-function variants can act through inflammasome-independent inflammatory mechanisms, showing the disease pathway is variant-dependent.\",\n      \"evidence\": \"In vitro PLC activity assay and whole-blood cytokine assays with IL-1 blockade\",\n      \"pmids\": [\"30619256\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Alternative inflammatory effector pathway for L848P not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the autoinhibitory map beyond the SH2 domains by showing a C2-domain GOF variant enhances BCR-triggered Ca2+ and ERK signaling.\",\n      \"evidence\": \"BCR-triggered Ca2+ flux and ERK phosphorylation by flow cytometry in patient cells and Plcg2-deficient DT40 reconstitution\",\n      \"pmids\": [\"31853824\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Structural contribution of C2 domain to autoinhibition not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed the Alzheimer's-protective P522R variant is a mild gain-of-function allele, linking PLCγ2 enzymatic tuning to reduced disease risk.\",\n      \"evidence\": \"Radioactive phospholipase, IP-One ELISA, and Ca2+ assays in transfected COS7/HEK293T cells\",\n      \"pmids\": [\"30711010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterologous system did not establish the cell type relevant to protection\", \"Did not link enzyme activity to a microglial phenotype\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed PLCG2 downstream of CSF1R in microglial/neuronal protective signaling, defining CSF1R/PLCG2/PKA/UCP2 and CSF1R/PLCG2/PKCε/CREB branches.\",\n      \"evidence\": \"Pharmacological epistasis (BLZ945, U73122) with phospho-pathway immunoblotting and functional readouts in a rat hypoxic-ischemic model\",\n      \"pmids\": [\"33101590\", \"32522286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, animal model\", \"Direct PLCγ2 substrate-to-PKA/PKCε link not biochemically demonstrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Positioned PLCG2 within TREM2 signal transduction in microglia and showed its requirement for amyloid-responsive microglial behavior.\",\n      \"evidence\": \"PLCG2-deficient and TREM2-deficient crosses into 5xFAD mice with bulk RNA-seq, immunostaining, and human transcriptomic correlation\",\n      \"pmids\": [\"40346446\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directionality of PLCG2-TREM2 regulatory relationship not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked the protective P522R allele to a specific microglial gain-of-function — enhanced antigen presentation and T cell engagement — providing a cellular mechanism for AD protection.\",\n      \"evidence\": \"P522R vs WT iPSC-microglia transplanted into chimeric AD mice with single-cell/bulk RNA-seq and CD8+ T cell histology\",\n      \"pmids\": [\"35142046\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Causal link between enzymatic hypermorphism and antigen-presentation phenotype not isolated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Systematically classified PLCG2 variants, revealing a dominant class of monoallelic loss-of-function alleles alongside gain-of-function alleles with distinct immune phenotypes including NK cell dysfunction.\",\n      \"evidence\": \"Mutagenesis and reconstitution in Plcg2-deficient DT40 cells with BCR Ca2+/ERK readouts and primary patient cell assays\",\n      \"pmids\": [\"37769878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of cell-type-selective phenotypes not resolved\", \"Did not define why NK cells are more sensitive than B cells\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established that full PLCG2 gene dosage is specifically required for NK cell function, showing haploinsufficiency causes NK immunodeficiency with preserved B cells.\",\n      \"evidence\": \"Whole-exome sequencing, mass cytometry, NK cytotoxicity/Ca2+ assays, and a Plcg2+/- mouse phenocopy\",\n      \"pmids\": [\"37714437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for NK-specific dosage sensitivity not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided direct biochemical evidence that autoinhibition operates through a catalytic–autoinhibitory domain interaction, disrupted by D993Y to drive Ca2+/MAPK/NF-κB/NFAT signaling.\",\n      \"evidence\": \"IP3 ELISA, Ca2+ flux, phospho-immunoblotting, NF-κB/NFAT luciferase reporters, and co-immunoprecipitation of domain interaction across HEK293T/COS-7/PLCG2-KO THP-1 cells\",\n      \"pmids\": [\"38965708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the interdomain interface not solved\", \"Did not test whether other GOF variants disrupt the same contact\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated a dominant-negative class of PLCG2 alleles, where in-frame deletion proteins fail to transmit BCR signaling, expanding the spectrum of pathogenic mechanisms beyond simple GOF/LOF.\",\n      \"evidence\": \"cDNA/whole-genome sequencing and reconstitution of deletion transcripts in Plcg2-deficient DT40 cells with BCR-triggered ERK readout\",\n      \"pmids\": [\"39667583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism by which deletion protein interferes with wild-type enzyme not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified epigenetic silencing of PLCG2 in cancer and a tumor-suppressive role, broadening its functional contexts beyond immune signaling.\",\n      \"evidence\": \"Methylation-specific/bisulfite PCR linking DNMT3B to PLCG2 promoter methylation, with xenograft tumor growth assays\",\n      \"pmids\": [\"39108206\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Effector pathway downstream of PLCG2 in colorectal cancer not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a chemotaxis-gating function for PLCγ2 in neutrophils via control of CAPRI membrane recruitment and Ras/PI3Kγ activity.\",\n      \"evidence\": \"Ca2+ imaging, CAPRI membrane localization, Ras/PI3Kγ activity, actin and chemotaxis assays in plcg2-knockdown neutrophils (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.04.07.647573\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, single lab\", \"Direct PLCγ2-CAPRI biochemical link not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified splice-based loss-of-function mechanisms, including an NMD-susceptible isoform lacking the Ca2+-binding domain generated by a risk allele.\",\n      \"evidence\": \"Minigene splicing in BV-2 cells, cycloheximide NMD assessment, and Ca2+ response comparison in transfected HEK293 cells\",\n      \"pmids\": [\"41459197\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Endogenous in vivo abundance of the isoform not quantified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolved allele-specific microglial consequences, with risk M28L phenocopying PLCG2 knockout and protective P522R enhancing cytokine responses and apoptosis resistance.\",\n      \"evidence\": \"Isogenic iPSC-derived microglia (P522R/M28L/KO) with bulk RNA-seq, cytokine, proliferation, apoptosis, and TREM2 expression assays\",\n      \"pmids\": [\"41066163\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism connecting M28L to TREM2 downregulation not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PLCγ2 dosage and activity translate into cell-type-selective phenotypes (NK vs B cells, microglia vs neurons) and the structural basis of its temperature-sensitive autoinhibition remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of the autoinhibited and activated states reported in the corpus\", \"Cell-type-specific effector wiring not mechanistically dissected\", \"Neuronal role of PLCG2 rests on preprint-level evidence\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 3, 13]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 7, 8, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 11, 12, 9]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TREM2\", \"CSF1R\", \"VCP\", \"CAPRI\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}